Durvalumab as Maintenance Following Chemoradiation for Unresectable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma Clinical Trial

— DESC  

Official title:

Durvalumab (MEDI4736) as Maintenance Treatment Following Chemoradiation for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (DESC).

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04054518
• Other study ID #: 1473/19
• Status: Not yet recruiting
• Phase: Phase 2
• Start date: October 1, 2019
• Est. completion date: October 1, 2022

Study information

• Verified date: August 2019
• Source: Instituto do Cancer do Estado de São Paulo
• Contact: Tiago B de Castria, MD PhD
• Phone: +551138934531
• Email: tiagobiachi[@]yahoo.com.br
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Single arm phase II trial designed to assess the efficacy of durvalumab treatment in terms of 6-month progression-free survival. We will include 22 patients who will receive 1500 mg durvalumab (MEDI4736) via IV infusion Q4W <<for up to a maximum of 12 months (up to 13 doses/cycles) with the last administration on week 48>> or <<until confirmed disease progression>> unless there is unacceptable toxicity, withdrawal of consent, or another discontinuation criterion is met. If a patient's weight falls to 30 kg or below for 1 week or longer ( ≥ 7 days) durvalumab will be permanently discontinued.

Description:

A) Study Title: Durvalumab (MEDI4736) as maintenance treatment following chemoradiation for locally advanced unresectable esophageal squamous cell carcinoma (DESC)

B) Protocol Number: ESR-17-12757

C) Clinical Phase: 2

D) Study Duration: 36 months

E) Investigational Product(s) and Reference Therapy: Durvalumab (MEDI4736)

F) Research Hypothesis: Is Durvalumab efficient in delay progression in patients with persistent disease after chemoradiation for locally advanced esophageal squamous cell carcinoma?

G) Objectives:

G1) Primary Objectives:

To assess the efficacy of durvalumab treatment in terms of 6-month progression-free survival.

G2) Secondary Objective(s):

To assess the incidence of grade 3 or higher toxicities; To further assess the efficacy of durvalumab in terms of overall survival, incidence of locoregional progression and incidence of distant progression.>>

G3) Exploratory Objective(s):

To investigate the relationship between immune biomarkers within the tumor microenvironment (immunohistochemistry) with efficacy outcomes with durvalumab

H) Study Design: Single arm phase II trial

I) Number of Centers: 1

J) Number of Patients:22

K) Study Population:

Patients with locally advanced unresectable or inoperable esophageal squamous cell carcinoma who had a persistent disease after completing definitive chemoradiotherapy, with no progressive disease.

L) Inclusion Criteria:

• Body weight >30kg and body mass index ≥ 16 kg / m2;

• Patients who are aphagic or able to ingest only liquids should also receive enteral nutritional support before inclusion in the study;

• Patients with histologically and/or cytologically confirmed esophageal or esophagogastric junction (Siewert I or II) squamous cell carcinoma, irrespective of PD-1/PD-L1 or any other biomarker expression;

• Patients who had a persistent disease 6-8 weeks after completing chemoradiotherapy with at least 50 Gy and platinum-based chemo and without clinical complete response or progressive disease;

• CT scans within 4 weeks revealing persistent disease;

• Must be included <12 weeks after completing chemoradiotherapy to ensure durvalumab begins no later than 16 weeks after completion of chemoradiotherapy;

• Patients unsuitable to salvage esophagectomy;

• All the tumor volume should have been treated with CRT (included in the radiation field); ECOG 0 - 1;

• Age 18 years or older;

• Life expectancy of higher than 3 months;

• Laboratory values must meet the following criteria: Absolute neutrophil count (ANC) > 1.5 (>1500 per mm3); Platelet count ≥ 100 x109/L. Hemoglobin >9.0 g/dL. Creatinine < 1.5 times institutional ULN or CrCl > 40 mL/min. AST (SGOT)/ALT (SGPT) ≤2.5 x institutional upper limit of normal. Serum bilirubin ≤ 1.5 times institutional ULN (This will not apply to patients with confirmed Gilbert's syndrome - persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology, who will be allowed only in consultation with their physician)

• All toxicities attributed to prior chemoradiotherapy other than alopecia, fatigue, or peripheral neuropathy must have resolved to grade 2 or less.

M) Exclusion Criteria:

• Presence of any site of metastatic disease, including lymph node which has not been included in radiation field;

• Are currently receiving or have had prior use of immunosuppressive medication within 28 days before the first dose of study drug (10 milligrams/day of prednisone or an equivalent corticosteroid is allowed);

• Received any immunotherapy for esophageal cancer;

• Has known active hepatitis B, hepatitis C or human immunodeficiency virus (HIV1/2 antibodies);

• Has known active or prior autoimmune disease, except for:

• skin diseases (vitiligo, psoriasis, alopecia)

• diabetes mellitus type 1, with hormone replacement

• hypothyroidism, with hormone replacement

• Receipt of live attenuated vaccination within 30 days prior to study entry.

• Grade 3 or higher pulmonary toxicity of dyspnea, hypoxia, or pneumonitis experienced during chemoradiation;

• Presence of tracheoesophageal fistula that has not been treated with endoprosthesis>>

N) Investigational Product(s), Dose and Mode of Administration:

Patients in the durvalumab (MEDI4736) monotherapy treatment group will receive 1500 mg durvalumab (MEDI4736) via IV infusion Q4W < O) Study Assessments and Criteria for Evaluation:

O.1) Safety Assessments:

Safety assessments will be performed in accordance with the National Cancer Institute Common Terminology Criteria, version 5.0.

At least every 4 weeks, during each visit, data on toxicity on treatment will be evaluated.

Laboratory analysis will also be performed at least every 4 weeks to assess toxicity.

O.2) Efficacy Assessments:

Patients will undergo tumor assessments with cross-sectional imaging at study site at start and then 8 ± 1w until complete 12 months after first dose; Patients who have disease control following completion of 12 months (13 cycles) of treatment will continue to have objective tumor assessment q12w ± 1w for more 12 months or until disease progression (whichever comes first); Patients who are withdrawn from durvalumab treatment for reasons other than confirmed PD (e.g toxicity) will continue to have objective tumor assessments q8w ± 1w until complete 12 months after first dose. Then, they will have objective tumor assessments q12w ± 1w for more 12 months (24 months after first dose) or until disease progression; Measurable target and nontarget lesions will be assessed according to Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1).

P) Statistical Methods and Data Analysis:

Safety analysis will be performed considering all enrolled patients who received at least one dose of durvalumab; Efficacy analysis will be performed using intention-to-treat approach; Will be used an alpha error of 0.05 (1-sided) and a power (1 - beta error) of 90%; Primary endpoint will be 6-month progression free survival rate; Secondary endpoints will be overall survival, incidence of locoregional progression and incidence of distant progression; Locoregional progression is defined when an in-field lesion (primary tumor or lymph nodes) is the first site of progression or in case of worsening dysphagia with an upper endoscopy revealing an unequivocal local progression; Distant progression is defined when an out-field lesion (lymph node, visceral, bone) is the first site of progression; We estimate 12 months of recruitment, with 2 patients per month; Overall survival will be estimated using Kaplan-Meier method.

Q) Sample Size Determination:

Single arm phase II trial; Will be estimated p0 (null-hypothesis 6-month PFS) as 10%; Will be estimated p1 (alternative hypothesis 6-month PFS) as 35%; With an estimated dropout rate of 10%, our sample size will be 22 patients.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 22
• Est. completion date: October 1, 2022
• Est. primary completion date: October 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Body weight >30kg and body mass index = 16 kg / m2;

2. Patients aphagic or able to ingest only liquids should also receive enteral nutritional sup-port before being included in the study;

3. Patients must have histologically confirmed esophageal or esophagogastric junction (Siewert I or II) squamous cell carcinoma, irrespective of PD-1/PD-L1 or other biomarkers expression;

4. Patients must have had a persistent disease 6-8 weeks after completing chemoradiotherapy with at least 50 Gy and platinum-based chemo and without complete response or progressive disease, based on upper endoscopy and/or CT scans;

5. Patients must have realized CT scans within 6-8 weeks after completion of chemoradiotherapy, revealing persistent disease;

6. Patients must be included <12 weeks after completing chemoradiotherapy;

7. Patients must be unsuitable to salvage esophagectomy, according multidisciplinary local board;

8. All the tumor volume should have been treated with CRT (included in the radiation field);

9. Eastern Cooperative Oncology Group (ECOG)>><<World Health Organisation (WHO) performance status of 0 or 1;

10. Male or female aged 18 years or older at time of study entry;

11. Life expectancy of > 12 weeks;

12. Adequate normal organ and marrow function as defined below:

• Haemoglobin =9.0 g/dL

• Absolute neutrophil count (ANC) 1.5 x (> 1500 per mm3)

• Platelet count =100 x 109/L

• Serum bilirubin =1.5 x institutional upper limit of normal (ULN). <<This will not apply to patients with confirmed Gilbert's syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physician.

• AST (SGOT)/ALT (SGPT) =2.5 x institutional upper limit of normal unless liver metastases are present, in which case it must be =5x ULN

• Measured creatinine clearance (CL) >40 mL/min or Calculated creatinine CL>40 mL/min by the Cockcroft-Gault formula (Cockcroft and Gault 1976) or by 24-hour urine collection for determination of creatinine clearance: CrCl, mL/min = (140 - age) × (weight, kg) × (0.85 if female) / (72 × Cr)

13. All toxicities attributed to prior chemoradiotherapy other than alopecia, fatigue, or peripheral neuropathy must have resolved to grade 2 or less;

Exclusion Criteria:

1. Patients with metastases including lymph node not included in the radiation field;

2. Patients currently receiving or have had prior use of immunosuppressive medication within 28 days before the first dose of study drug (10 milligrams/day of prednisone or an equivalent corticosteroid is allowed);

3. Received any immunotherapy for esophageal cancer;

4. Patients with active hepatitis B, hepatitis C or human immunodeficiency virus (HIV1/2 antibodies);

5. Has known active or prior autoimmune disease, except for:

• skin diseases (vitiligo, psoriasis, alopecia)

• diabetes mellitus type 1, with hormone replacement

• hypothyroidism, with hormone replacement

6. Receipt of live attenuated vaccine within 30 days prior to the first dose of IP.

7. Grade 3 or higher pulmonary toxicity of dyspnea, hypoxia, or pneumonitis experienced during chemoradiation;

8. Presence of fistula between esophagus and trachea unless treated with endoscopic prosthesis.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Squamous Cell
• Esophageal Squamous Cell Carcinoma

Intervention

Drug:
• Durvalumab
Durvalumab (MEDI4736) will be supplied as a 500-mg vial solution for infusion after dilution.

Locations

Country	Name	City	State
Brazil	Instituto do Câncer do Estado de São Paulo	São Paulo

Sponsors (1)

Lead Sponsor	Collaborator
Tiago Biachi

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Six-month progression-free survival according to immune biomarkers	Percentage of subjects who remain progression free at 6 months according to immune-related or response-related markers by immunohistochemistry (PD-1, PD-L1, CTLA-4, CD3, CD4, CD8, CD45RO, forkhead box P3, granzyme B, OX40, cleaved caspase 3 and Ki67).	6 months
Primary	Six-month progression-free survival	The primary endpoint is the percentage of subjects who remain progression free at 6 months using investigator assessments according to RECIST 1.1	6 months
Secondary	Incidence of Treatment-Related Adverse Events [Safety and Tolerability]	Incidence of grade 3 or higher toxicities graded according to NCI CTCAE (version 5.0)	From time of informed consent through treatment period (12 months) or up to 12 months post last dose of study treatment.
Secondary	Overall survival	Time from randomization until death from any cause.	From time of informed consent until the date of death from any cause, assessed up to 60 months
Secondary	Incidence of locoregional progression	Defined as the number of patients whose the first site of progression was in field.	From time of informed consent through treatment period (12 months) or up to 12 months post last dose of study treatment.
Secondary	Incidence of distant progression	Defined as the number of patients whose the first site of progression was distant.	From time of informed consent through treatment period (12 months) or up to 12 months post last dose of study treatment.